Phase
Alumni
Apoglyx
Apoglyx is a pre-clinical stage virtual biotech company with the aim to develop an oral therapy for type 2 diabetes patients, which are not adequately addressed by standard therapy. The treatment concept is based on the studies of Swedish and Danish researchers, which have discovered a novel mechanism for inhibiting hepatic glucose production.
Preben Bruun-Nyzell is an executive with more than 20 years international experience. He is co-founder of 2A Pharma and served as CFO from 2016-2019. He was previously Chief Financial Officer of Qatalum in Qatar, an aluminum producer with annual sales of USD 1.5 billion, and has held senior positions with EMAL in Abu Dhabi, Arqaam Capital in Dubai, Accenture and PwC in London and Hoffmann-La Roche AG in Basel, Switzerland. Preben holds a degree in Business Administration from Lancaster University in the UK and Università Bocconi, Milan, Italy.
Excellence in solid material analysis
Amplify the efficacy of pharmaceutical treatments
Simplify medicine information through digital services
A "check-in buddy" for the elderly
Excellence in inhaler performance
Behavioral coaching app
Antibiotic-free treatment for vaginal bacterial infections
Digital tool for meeting an allergy doctor
Cutting-Edge Histological Solutions for Pharma Industry
Digital communication tool for titrating medicine
Mobile systems for movement analysis
Innovative solutions for better health care
GPS tracker system for elderly
Drug delivery platform
Healthtech for children with eating challenges
Digital health management tool
Short chain fatty acids can be delivered to the colon
Therapeutics after stroke
Starch pickering emulsion technology
Measuring thyroid hormone levels
Gene editing analysis solution
Cost-effective & rapid COVID-19 diagnostic test
eHealth clinic for obesity treatment
